Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$36.06 - $117.21 $118,457 - $385,034
3,285 New
3,285 $361,000
Q2 2022

Aug 15, 2022

BUY
$22.39 - $38.94 $638,831 - $1.11 Million
28,532 New
28,532 $805,000

Others Institutions Holding RXDX

About Prometheus Biosciences, Inc.


  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track Gyon Technologies Capital Management, LP Portfolio

Follow Gyon Technologies Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.